XIAP and cancer: Treatment of XIAP siRNA in combination with paclitaxel, cisplatin, fluorouracil, and etoposide enhanced chemosensitivity in esophageal carcinoma cell lines demonstrating that knockdown of XIAP may be a strategy for cancer therapy in patients with esophageal carcinoma (46).